Request a Proposal

Maximising digital communications with physicians in China

Find out how to be involved in our new syndicated study

We are currently conducting a syndicated study to assess the impact of COVID-19 on how Chinese doctors use digital channels to interact with pharma companies through interviews with 270 key specialists active in treating patients across the following therapy areas.


Number of interviews

Cardiology 30
Dermatology  30 
Endocrinology 30
Gastrology  30
Hepatology  30
Nephrology 30
Oncology  30
Respiratory 30
Rheumatology 30

All respondents will be:

  • Hospital based specialists, active in prescription of innovative, branded treatments
  • Working in level 3 hospitals
  • Across Tier 1-3 cities 
  • All respondents will be at Doctor-in-Charge, Vice Chief Doctor and Chief Doctor level 

Our study will explore how the use of digital channels will continue to evolve amongst HCPs who have been forced to change the way they interact with pharma due to COVID-19.

Specifically, the study will focus on the following:

Technographic profile of target HCPs

  • Segmentation of HCPs according to how they use digital channels in their work
  • Allowing clients to target different archetypes and deliver tailored communication

Use of digital channels 

  • Usage and satisfaction with digital channels? How frequently? What duration? How do they access? What time of day? What do they use each channel for?
  • Rating of channels on aspects including ease of access, provision of useful, trustworthy information and impact on their decision making

Explore digital uptake post COVID-19

  • Impact of COVID-19 on communication and digital channels and identifying the optimum marketing mix
  • What is the role of the sales rep in post COVID-19 China? Including examples of innovative interactions with pharma during/after the lockdown 

This study is relevant for those seeking to maximise the use of digital channels in the marketing mix by understanding the prescriber’s expectations and future usage of digital communications, including:

  • Biopharmaceutical and vaccine manufacturers who either have treatments currently available in Tier 3 hospitals or in late Stage 3 development
  • Advertising, marketing, PR and medical communication agencies working in China

Reasons to purchase our syndicated report:

Cost effective

Cost is spread out across multiple clients, hence it can be a more cost effective research solution to your needs


If investing in the study early in the set-up phase, you will have the ability to help shape aspects of the methodology and potential for you to include a selection of proprietary questions

Rapid availability

Results from this study will be available in July 2020

If you would like to receive a more detailed overview of our proposed study as well as further information about how we can best support you and your team, please contact us using the contact form below.

Request more information

By completing this form you agree to receive email communications, including free resources, webinars and event invitations. You can update your preferences or opt out at any time.

Marc Yates

Director Asia Pacific and Emerging Markets

Marc is head of RP's dedicated Emerging Markets division. He has 35 years’ experience of market research, and has specialized in healthcare research since 1996. Marc spent 15 years in Asia, including postings in Shanghai, Hong Kong and Singapore. In 2012 he relocated back to London working closely with pharma companies looking to maximise their ROI in emerging markets. Marc is a regular speaker at industry events and has presented papers on Emerging Markets at EphMRA and PBIRG conferences.

Marc Yates